Home » Healthcare » Pharmaceuticals » Biologics For Systemic Lupus Erythematosus Market

Biologics For Systemic Lupus Erythematosus Market By Route of (Administration Outlook, Oral, Intravenous, Subcutaneous)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global biologics for systemic lupus erythematosus market is segmented by route of administration outlook and region. Oral biologics for systemic lupus erythematosus is the most popular, while subcutaneously and adults are the primary user segments. North America was leading the market growth.

The global biologics for systemic lupus erythematosus market has several drivers, including the inclusion of innovation in the pipeline for development. In addition, the increased incidence of autoimmune diseases, particularly systemic lupus erythematosus (SLE), is driving higher demand for systemic lupus erythematosus (SLE) medications. The market share for pharmaceuticals treating systemic lupus erythematosus (SLE) is also anticipated to increase due to some novel prospective treatments now undergoing Phase III research. However, the market also faces significant challenges, such as insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.

Nonetheless, the global biologics for systemic lupus erythematosus market offers significant growth opportunities, including increasing R&D investment. Creating novel SLE treatments is receiving significant funding from businesses and academic organizations, further accelerating the market’s expansion.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global biologics for systemic lupus erythematosus market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 8.50% between 2023 and 2030. The market was valued at USD 0.58 billion in 2022 and is expected to reach USD 1.03 billion in 2030.

What Are The Main Drivers Of The Global Biologics for systemic lupus erythematosus Market?

The global biologics for systemic lupus erythematosus market is driven by several factors. SLE is becoming more common, especially among women of childbearing age, and affects millions globally.

What Are The Major Challenges Faced By The Global Biologics for systemic lupus erythematosus Market?

The global biologics for systemic lupus erythematosus market also faces several challenges, including insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.

What Are The Growth Opportunities In The Global Biologics for systemic lupus erythematosus Market?

The global biologics for systemic lupus erythematosus market offers significant growth opportunities, including increasing R&D investment. Creating novel SLE treatments is receiving significant funding from businesses and academic organizations, further accelerating the market’s expansion.

Executive Summary

Overview of the Global Biologics for systemic lupus erythematosus Market

The global biologics for systemic lupus erythematosus market has been steadily growing in recent years, driven by SLE is becoming more common, especially among women of childbearing age, and affects millions of individuals globally. The industry is distinguished by a vast range of administrative outlooks catering to various client tastes.

Market Definition

An autoimmune condition known as systemic lupus erythematosus can affect any organ system in the body. Because our immune system perceives our body as foreign, it assaults it, resulting in autoimmune disease. People suffering from this condition can lead regular lives. This condition is most common in women and primarily affects women aged 25 to 45. Lupus symptoms include knee pain, adnexal discomfort, hair loss, kidney problems, skin irritation, and headaches, among many others. Biologics for autoimmune diseases significantly improve treatment and are gradually gaining physician trust. The launch of new natural or biological remedies in the advancement pipeline, which will increase treatment options and drug costs, is expected to accelerate the market’s income age. Certain new hopeful drugs currently in Phase III trials are expected to expand the market, as these medications may target the lupus nephritis patient subset with a couple of attractive options, and significant neglect should be fulfilled.

Market Insights

The global demand for biologics for systemic lupus erythematosus was valued at USD 0.58 Billion in 2022 and is expected to reach USD 1.03 Billion in 2030, growing at a CAGR of 8.50% between 2023 and 2030.
Oral is the leading segment by route of administration outlook and held over 35% share in terms of value in 2022, while the subcutaneous segment is likely to exhibit the fastest CAGR during the forecast period.
North America is fueling the growth of the biologics for systemic lupus erythematosus industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 50% share in 2022. Europe held over 22% share in 2022.

The increased prevalence of SLE, combined with coverage for specialty medications and improved healthcare infrastructure, is fueling regional market expansion. At the same time, the main restraints are insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.
Increasing R&D investment and creating novel SLE treatments receiving significant funding from businesses and academic organizations are the major opportunities in the market.

Segmentation by Route of Administration Outlook

Oral is the leading segment by route of administration outlook and held over 35% share in value in 2022.
The subcutaneous segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Region

North America is fueling the growth of the biologics for systemic lupus erythematosus industry with over one-third share in 2022.
Asia Pacific and Europe collectively account for just under 50% share in 2022, with Europe holding over 22% share in the same year.
The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for biologics for systemic lupus erythematosus.

The increasing demand for biologics for systemic lupus erythematosus can be attributed to SLE becoming more common, especially among women of childbearing age, affecting millions globally. However, the market is restrained by insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.

The United States is one of the largest markets for biologics for systemic lupus erythematosus in North America, with a significant share of the market. The increased prevalence of SLE, combined with the inclusion of powerful drugs and a solid healthcare infrastructure framework, contributes to the local market’s growth.

China is also a major market for biologics for systemic lupus erythematosus in the Asia Pacific region, with a significant market share. Systemic Lupus Erythematosus Market share in the Asia-Pacific region is also considerable and quickly rising, with major growth prospects in countries such as China. The rising prevalence of SLE, the expanding healthcare sector, and the growing middle-class population are important drivers driving the Asia-Pacific SLE market.

Overall, the increasing demand for biologics for systemic lupus erythematosus can be attributed to SLE becoming more common, especially among women of childbearing age, and affecting millions globally.

While the biologics for systemic lupus erythematosus market is growing, it faces challenges from insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment. Manufacturers are innovating and forming partnerships to stay competitive.

The Increasing Prevalence Of Autoimmune Diseases, Particularly Systemic Lupus Erythematosus (SLE)

The global market for systemic lupus erythematosus (SLE) medications is predicted to grow due to the increasing prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE). The development of newer SLE treatments enhanced the availability of biosimilar pharmaceuticals. It raised support for expanding research areas for novel drug molecules, increasing sales of systemic lupus erythematosus (SLE) drugs and pushing the worldwide systemic lupus erythematosus (SLE) drugs market.

Increased awareness of sickness diagnosis and treatment and ongoing research and development procedures for novel therapeutic molecules are important drivers of the global systemic lupus erythematosus (SLE) medicine market. Additionally, systemic lupus erythematosus (SLE) medicine sales may be hindered by concerns about the efficacy and safety of SLE-controlling medications.

Strict Regulatory Environment, Hefty Drug Development Costs

The market has faced hurdles, including a rigorous regulatory environment, high drug development costs, etc. One of the key obstacles for the systemic lupus erythematosus industry is the stringent regulatory environment. Historically, all vaccines, medical devices, and useful drugs designed to treat specific diseases have gone through comprehensive testing in clinical trials to establish their safety and feasibility in treating the disease. These trials take a long time, and the rules and regulations that govern them are extremely strict. As a result, research organizations and pharmaceutical businesses must make slow progress toward regulatory approvals. The severe regulations would stifle the market’s expansion.

Advancement in technology

The market is expected to grow rapidly over the forecast period due to numerous recent trends, such as increased clinical trials, adoption of stem cell therapy, increased public awareness, and so on. One of the most promising new medical approaches for treating lupus may be stem cell therapy, particularly for patients who do not respond well to more standard types of treatment. Stem cell therapy is becoming more popular as a novel and advanced method of treating lupus, which will help the SLE market’s growth.

Competitive Landscape

Key Players

The global biologics for systemic lupus erythematosus market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

Pfizer
Roche
GlaxoSmithKline
Sanofi
AbbVie
Novartis
Merck & Co.
Bristol-Myers Squibb
Celgene
Janssen Global Services
LLC
Eli Lilly and Company
UCB
AstraZeneca
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson
Astellas Pharma, Inc.
Biotest AG
Coherus BioSciences

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market.

The major players in the global biologics for systemic lupus erythematosus market constantly strive to stay ahead by introducing new products and innovations.

On March 9, 2011, the FDA authorized belimumab, a medication particularly for SLE, after a 50-year wait. Human Genome Sciences Inc. created the first-ever targeted biological therapy for treating SLE patients.

Benlysta, developed with GlaxoSmithKline, is expected to lead systemic lupus erythematosus (SLE) medicine market sales in the next years due to its superior safety profile and clinical trial performance.

The symptoms of SLE can be controlled with NSAIDs like aspirin and ibuprofen, which are often recommended medications.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

SLE is becoming more common, especially among women of childbearing age, and affects millions of individuals globally, driving market growth
Market segmented by route of administration outlook and region.
Oral biologics for systemic lupus erythematosus are the most popular, with subcutaneous as the primary user segment.
North America is leading market growth; the market is highly competitive with key players including Pfizer, Roche, GlaxoSmithKline, Sanofi, AbbVie, Novartis, Merck & Co., Bristol-Myers Squibb, Celgene, Janssen Global Services, LLC, Eli Lilly and Company, UCB, AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Astellas Pharma, Inc., Biotest AG, and Coherus BioSciences.

Future Outlook

Positive outlook for the global biologics for systemic lupus erythematosus market with significant growth potential in the North American region

Increasing R&D investment and the creation of novel SLE treatments are receiving significant funding from businesses and academic organizations, further accelerating the market’s expansion.

Challenges from insufficient access to care and knowledge about SLE, especially among healthcare professionals, could lead to a false positive and delayed treatment.
Key players to focus on product innovation, expanding market reach and maintaining competitive pricing to stay ahead in the market.

Segmentation

By Route of Administration Outlook
- Oral
- Intravenous
- Subcutaneous
By Region

North America
- The US.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Biologics For Systemic Lupus Erythematosus Market
2.2. Global Biologics For Systemic Lupus Erythematosus Market, By Route of Administration Outlook
2.3. Global Biologics For Systemic Lupus Erythematosus Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Biologics For Systemic Lupus Erythematosus Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Smart Shopping Market Drivers
3.2.2. Smart Shopping Market Restraints
3.2.3. Smart Shopping Market Opportunities
3.2.4. Major Smart Shopping Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Route of Administration Outlook
3.5.2. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Route of Administration Outlook Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Biologics For Systemic Lupus Erythematosus Market, By Route of Administration Outlook
7.1. Global Biologics For Systemic Lupus Erythematosus Market Overview, by Route of Administration Outlook
7.1.1. Global Biologics For Systemic Lupus Erythematosus Market Revenue Share, By Route of Administration Outlook , 2022 Vs 2030 (in %)
7.2. Oral
7.2.1. Global Biologics For Systemic Lupus Erythematosus Market, By Region, 2017-2030 (US$ Bn)
7.3. Intravenous
7.3.1. Global Biologics For Systemic Lupus Erythematosus Market, By Region, 2017-2030 (US$ Bn)
7.4. Subcutaneous
7.4.1. Global Biologics For Systemic Lupus Erythematosus Market, By Region, 2017-2030 (US$ Bn)

8. Global Biologics For Systemic Lupus Erythematosus Market, By Region
8.1. Global Biologics For Systemic Lupus Erythematosus Market Overview, by Region
8.1.1. Global Biologics For Systemic Lupus Erythematosus Market, By Region, 2022 vs 2030 (in%)
8.2. Route of Administration Outlook
8.2.1. Global Biologics For Systemic Lupus Erythematosus Market, By Route of Administration Outlook, 2017-2030 (US$ Bn)

9. North America Biologics For Systemic Lupus Erythematosus Market Analysis
9.1. North America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2030(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. North America Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2030 (US$ Bn)
9.2.1. North America Biologics For Systemic Lupus Erythematosus Market, by Country, 2022 Vs 2030 (in%)
9.2.2. U.S.
9.2.2.1. U.S. Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.2.2. U.S. Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
9.2.3. Canada
9.2.3.1. Canada Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.3.2. Canada Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
9.2.4. Mexico
9.2.4.1. Mexico Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.4.2. Mexico Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)

10. Europe Biologics For Systemic Lupus Erythematosus Market Analysis
10.1. Europe Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Europe Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2030 (US$ Bn)
10.2.1. Europe Biologics For Systemic Lupus Erythematosus Market, by Country, 2022 Vs 2030 (in%)
10.2.2. Germany
10.2.2.1. Germany Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.2.2. Germany Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
10.2.3. France
10.2.3.1. France Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.3.2. France Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
10.2.4. UK
10.2.4.1. UK Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.4.2. UK Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
10.2.5. Italy
10.2.5.1. Italy Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.5.2. Italy Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
10.2.6. Spain
10.2.6.1. Spain Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.6.2. Spain Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
10.2.7. Rest of Europe
10.2.7.1. Rest of Europe Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.7.2. Rest of Europe Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)

11. Asia Pacific Biologics For Systemic Lupus Erythematosus Market Analysis
11.1. Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2030 (US$ Bn)
11.2.1. Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Country, 2022 Vs 2030 (in%)
11.2.2. China
11.2.2.1. China Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.2.2. China Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
11.2.3. Japan
11.2.3.1. Japan Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.3.2. Japan Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
11.2.4. India
11.2.4.1. India Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.4.2. India Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
11.2.5. South Korea
11.2.5.1. South Korea Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.5.2. South Korea Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
11.2.6. South-East Asia
11.2.6.1. South-East Asia Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.6.2. South-East Asia Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
11.2.7. Rest of Asia Pacific
11.2.7.1. Rest of Asia Pacific Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.7.2. Rest of Asia Pacific Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)

12. Latin America Biologics For Systemic Lupus Erythematosus Market Analysis
12.1. Latin America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Latin America Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2030 (US$ Bn)
12.2.1. Latin America Biologics For Systemic Lupus Erythematosus Market, by Country, 2022 Vs 2030 (in%)
12.2.2. Brazil
12.2.2.1. Brazil Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.2.2. Brazil Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
12.2.3. Argentina
12.2.3.1. Argentina Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.3.2. Argentina Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
12.2.4. Rest of Latin America
12.2.4.1. Rest of Latin America Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.4.2. Rest of Latin America Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)

13. Middle East and Africa Biologics For Systemic Lupus Erythematosus Market Analysis
13.1. Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2030 (US$ Bn)
13.2.1. Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Country, 2022 Vs 2030 (in%)
13.2.2. GCC Countries
13.2.2.1. GCC Countries Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.2.2. GCC Countries Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
13.2.3. South Africa
13.2.3.1. South Africa Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.3.2. South Africa Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)
13.2.4. Rest of Middle East and Africa
13.2.4.1. Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.4.2. Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus, By Route of Administration Outlook, 2017-2030 (US$ Bn)

14. Company Profiles
14.1. Pfizer
14.1.1. Company Overview
14.1.2. Products/Services Portfolio
14.1.3. Geographical Presence
14.1.4. Financial Summary
14.1.4.1. Market Revenue and Net Profit (2019-2022)
14.1.4.2. Business Segment Revenue Analysis
14.1.4.3. Geographical Revenue Analysis
14.2. Roche
14.3. GlaxoSmithKline
14.4. Sanofi
14.5. AbbVie
14.6. Novartis
14.7. Merck & Co.
14.8. Bristol-Myers Squibb
14.9. Celgene
14.10. Janssen Global Services
14.11. LLC
14.12. Eli Lilly and Company
14.13. UCB
14.14. AstraZeneca
14.15. Teva Pharmaceutical Industries Ltd.
14.16. Johnson & Johnson
14.17. Astellas Pharma, Inc.
14.18. Biotest AG
14.19. Coherus BioSciences

List of Figures
FIG. 1 Global Biologics For Systemic Lupus Erythematosus Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Biologics For Systemic Lupus Erythematosus Market Segmentation
FIG. 4 Global Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2022 (US$ Bn)
FIG. 5 Global Biologics For Systemic Lupus Erythematosus Market, by Mode of Sales, 2022 (US$ Bn)
FIG. 6 Global Biologics For Systemic Lupus Erythematosus Market, by Application, 2022 (US$ Bn)
FIG. 7 Global Biologics For Systemic Lupus Erythematosus Market, by Geography, 2022 (US$ Bn)
FIG. 8 Attractive Investment Proposition, by Route of Administration Outlook, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Biologics For Systemic Lupus Erythematosus Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Biologics For Systemic Lupus Erythematosus Market Manufacturers, 2022
FIG. 12 Global Biologics For Systemic Lupus Erythematosus Market Value Contribution, By Route of Administration Outlook, 2022 & 2030 (Value %)
FIG. 13 Global Biologics For Systemic Lupus Erythematosus Market, by Oral, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Biologics For Systemic Lupus Erythematosus Market, by Intravenous, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Biologics For Systemic Lupus Erythematosus Market, by Subcutaneous, Value, 2017-2030 (US$ Bn)
FIG. 16 North America Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 17 U.S. Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 18 Canada Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 19 Europe Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 20 Germany Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 21 France Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 22 U.K. Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 23 Italy Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 24 Spain Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 25 Rest of Europe Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 26 Asia Pacific Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 27 China Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 28 Japan Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 29 India Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 30 South Korea Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 31 South-East Asia Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 32 Rest of Asia Pacific Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 33 Latin America Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 34 Brazil Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 35 Mexico Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 36 Rest of Latin America Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 37 Middle East & Africa Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 38 GCC Countries Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 39 South Africa Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)
FIG. 40 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Biologics For Systemic Lupus Erythematosus Market
TABLE 2 Global Biologics For Systemic Lupus Erythematosus Market: Market Drivers Impact Analysis
TABLE 3 Global Biologics For Systemic Lupus Erythematosus Market: Market Restraints Impact Analysis
TABLE 4 Global Biologics For Systemic Lupus Erythematosus Market, by Competitive Benchmarking, 2022
TABLE 5 Global Biologics For Systemic Lupus Erythematosus Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Biologics For Systemic Lupus Erythematosus Market, by Key Strategies Analysis, 2022
TABLE 7 Global Biologics For Systemic Lupus Erythematosus Market, by Oral, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Biologics For Systemic Lupus Erythematosus Market, by Oral, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Biologics For Systemic Lupus Erythematosus Market, by Intravenous, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Biologics For Systemic Lupus Erythematosus Market, by Intravenous, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Biologics For Systemic Lupus Erythematosus Market, by Subcutaneous, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Biologics For Systemic Lupus Erythematosus Market, by Subcutaneous, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 14 Global Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 15 Global Biologics For Systemic Lupus Erythematosus Market, by Region, 2017-2022 (US$ Bn)
TABLE 16 Global Biologics For Systemic Lupus Erythematosus Market, by Region, 2023-2030 (US$ Bn)
TABLE 17 North America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 18 North America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 19 North America Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2022 (US$ Bn)
TABLE 20 North America Biologics For Systemic Lupus Erythematosus Market, by Country, 2023-2030 (US$ Bn)
TABLE 21 United States Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 22 United States Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 23 Canada Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 24 Canada Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 25 Mexico Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 26 Mexico Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 27 Europe Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 28 Europe Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 29 Europe Biologics For Systemic Lupus Erythematosus Market, by Country, 2017-2022 (US$ Bn)
TABLE 30 Europe Biologics For Systemic Lupus Erythematosus Market, by Country, 2023-2030 (US$ Bn)
TABLE 31 Germany Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 32 Germany Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 33 France Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 34 France Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 35 United Kingdom Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 36 United Kingdom Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 37 Italy Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 38 Italy Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 39 Spain Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 40 Spain Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 41 Rest of Europe Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 42 Rest of Europe Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 43 Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 44 Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 45 China Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 46 China Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 47 Japan Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 48 Japan Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 49 India Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 50 India Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 51 South Korea Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 52 South Korea Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 53 South-East Asia Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 54 South-East Asia Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 55 Rest of Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 56 Rest of Asia Pacific Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 57 Latin America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 58 Latin America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 59 Brazil Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 60 Brazil Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 61 Argentina Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 62 Argentina Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 63 Rest of Latin America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 64 Rest of Latin America Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 65 Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 66 Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 67 GCC Countries Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 68 GCC Countries Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 69 South Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 70 South Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 71 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2017-2022 (US$ Bn)
TABLE 72 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Route of Administration Outlook, 2023-2030 (US$ Bn)
TABLE 73 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Modes of Sales, 2017-2022 (US$ Bn)
TABLE 74 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Modes of Sales, 2023-2030 (US$ Bn)
TABLE 75 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Application, 2017-2022 (US$ Bn)
TABLE 76 Rest of Middle East and Africa Biologics For Systemic Lupus Erythematosus Market, by Application, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global biologics for systemic lupus erythematosus market?

The global biologics for systemic lupus erythematosus market was valued at USD 0.58 Billion in 2022.

What is the expected growth rate of the biologics for systemic lupus erythematosus market between 2023 and 2030?

The biologics for systemic lupus erythematosus market is expected to grow at a CAGR of 8.50% between 2023 and 2030, reaching USD 1.03 Billion in 2030.

Which segment is leading the market share regarding the route of administration outlook?

Oral is the leading segment by route of administration outlook, holding over 35% share in terms of value in 2022.

Which segment is expected to post the highest CAGR during the forecast period?

The subcutaneous segment is expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the biologics for systemic lupus erythematosus industry?

North America is fueling the growth of the biologics for systemic lupus erythematosus industry, with over one-third share in 2022.

Who are the major players in the global biologics for systemic lupus erythematosus market?

The top players include Pfizer, Roche, GlaxoSmithKline, Sanofi, AbbVie, Novartis, Merck & Co., Bristol-Myers Squibb, Celgene, Janssen Global Services, LLC, Eli Lilly and Company, UCB, AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Astellas Pharma, Inc., Biotest AG, and Coherus BioSciences.

What are the major market drivers of the biologics for the systemic lupus erythematosus industry?

SLE is becoming more common, especially among women of childbearing age, and affects millions of individuals globally are the major market drivers.

What are the major market restraints of the biologics for the systemic lupus erythematosus industry?

The major market restraints are insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.

What are the major market opportunities of biologics for the systemic lupus erythematosus industry?

Increasing R&D investment, The creation of novel SLE treatments is receiving significant funding from businesses and academic organizations, which are the major opportunities in the biologics for systemic lupus erythematosus industry.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –